<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:media="http://search.yahoo.com/mrss/" xmlns:content="http://purl.org/rss/1.0/modules/content/" version="2.0">
  <channel>
    <title>Aaj TV English News - World</title>
    <link>https://english.aaj.tv/</link>
    <description>Aaj TV English</description>
    <language>en-Us</language>
    <copyright>Copyright 2026</copyright>
    <pubDate>Thu, 23 Apr 2026 14:31:24 +0500</pubDate>
    <lastBuildDate>Thu, 23 Apr 2026 14:31:24 +0500</lastBuildDate>
    <ttl>60</ttl>
    <item xmlns:default="http://purl.org/rss/1.0/modules/content/">
      <title>India halts cough syrup production at factory after Gambia deaths</title>
      <link>https://english.aaj.tv/news/30300964/india-halts-cough-syrup-production-at-factory-after-gambia-deaths</link>
      <description>&lt;p&gt;&lt;strong&gt;NEW DELHI: Indian authorities have halted production of cough syrup at a factory of Maiden Pharmaceuticals, a state minister said on Wednesday, after a WHO report that the medicine may be linked to the deaths of dozens of children in the Gambia.&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;The health minister in Haryana state, Anil Vij, told &lt;em&gt;Reuters&lt;/em&gt; partner &lt;em&gt;ANI&lt;/em&gt; that authorities inspected a Maiden factory in the town of Sonepat in the state and found 12 violations of good practices. Production was ordered stopped, Vij said.&lt;/p&gt;
&lt;p&gt;The WHO said last week that laboratory analysis of four Maiden products-Promethazine Oral Solution, Kofexmalin Baby Cough Syrup, Makoff Baby Cough Syrup and Magrip N Cold Syrup - had “unacceptable” amounts of diethylene glycol and ethylene glycol, which can be toxic and lead to acute kidney injury.&lt;/p&gt;
&lt;p&gt;Gambian police, in a preliminary investigation report on Tuesday, said that the deaths of 69 children from acute kidney injury were linked to the cough syrups made in India and imported via a US-based company.
It is one of the worst such incidents involving drugs from India, often dubbed a “pharmacy of the world”.&lt;/p&gt;
&lt;p&gt;News website &lt;em&gt;Moneycontrol&lt;/em&gt; earlier quoted the Haryana drugs controller as saying in a report that Maiden did not perform quality testing of propylene glycol, diethylene glycol and ethylene glycol, while certain batches of propylene glycol did not have the manufacturing and expiry dates.&lt;/p&gt;
&lt;p&gt;Diethylene glycol and ethylene glycol are used in antifreeze and brake fluids and other industrial applications but also as a cheaper alternative in some pharmaceutical products to glycerine, a solvent or thickening agent in many cough syrups.&lt;/p&gt;
&lt;p&gt;Maiden executive Naresh Kumar Goyal declined to comment. He told Reuters last week that the company was trying to find out from its buyer what had happened in the Gambia.&lt;/p&gt;
&lt;p&gt;However public health activist Dinesh Thakur, updated about the situation in a tweet as;&lt;/p&gt;
&lt;p&gt;    &lt;figure class='media  w-full  w-full  media--stretch    media--uneven  media--stretch'&gt;
        &lt;div class='media__item  media__item--twitter  '&gt;&lt;span&gt;
    &lt;blockquote class="twitter-tweet" lang="en"&gt;
        &lt;a href="https://twitter.com/d_s_thakur/status/1579843449859510273?s=20&amp;amp;t=-O1PehhNthym92Io_kzyoA"&gt;&lt;/a&gt;
    &lt;/blockquote&gt;
&lt;/span&gt;&lt;/div&gt;
        
    &lt;/figure&gt;&lt;/p&gt;
&lt;p&gt;India’s health ministry said last week that samples of all four Maiden products that had been exported to the Gambia had been sent for testing to a federal laboratory and the results would “guide the further course of action as well as bring clarity on the inputs received/to be received from WHO.”&lt;/p&gt;
&lt;p&gt;The syrups had been approved for export only to the Gambia,
India says although the WHO says they may have gone elsewhere
through informal markets.&lt;/p&gt;
</description>
      <content:encoded xmlns="http://purl.org/rss/1.0/modules/content/"><![CDATA[<p><strong>NEW DELHI: Indian authorities have halted production of cough syrup at a factory of Maiden Pharmaceuticals, a state minister said on Wednesday, after a WHO report that the medicine may be linked to the deaths of dozens of children in the Gambia.</strong></p>
<p>The health minister in Haryana state, Anil Vij, told <em>Reuters</em> partner <em>ANI</em> that authorities inspected a Maiden factory in the town of Sonepat in the state and found 12 violations of good practices. Production was ordered stopped, Vij said.</p>
<p>The WHO said last week that laboratory analysis of four Maiden products-Promethazine Oral Solution, Kofexmalin Baby Cough Syrup, Makoff Baby Cough Syrup and Magrip N Cold Syrup - had “unacceptable” amounts of diethylene glycol and ethylene glycol, which can be toxic and lead to acute kidney injury.</p>
<p>Gambian police, in a preliminary investigation report on Tuesday, said that the deaths of 69 children from acute kidney injury were linked to the cough syrups made in India and imported via a US-based company.
It is one of the worst such incidents involving drugs from India, often dubbed a “pharmacy of the world”.</p>
<p>News website <em>Moneycontrol</em> earlier quoted the Haryana drugs controller as saying in a report that Maiden did not perform quality testing of propylene glycol, diethylene glycol and ethylene glycol, while certain batches of propylene glycol did not have the manufacturing and expiry dates.</p>
<p>Diethylene glycol and ethylene glycol are used in antifreeze and brake fluids and other industrial applications but also as a cheaper alternative in some pharmaceutical products to glycerine, a solvent or thickening agent in many cough syrups.</p>
<p>Maiden executive Naresh Kumar Goyal declined to comment. He told Reuters last week that the company was trying to find out from its buyer what had happened in the Gambia.</p>
<p>However public health activist Dinesh Thakur, updated about the situation in a tweet as;</p>
<p>    <figure class='media  w-full  w-full  media--stretch    media--uneven  media--stretch'>
        <div class='media__item  media__item--twitter  '><span>
    <blockquote class="twitter-tweet" lang="en">
        <a href="https://twitter.com/d_s_thakur/status/1579843449859510273?s=20&amp;t=-O1PehhNthym92Io_kzyoA"></a>
    </blockquote>
</span></div>
        
    </figure></p>
<p>India’s health ministry said last week that samples of all four Maiden products that had been exported to the Gambia had been sent for testing to a federal laboratory and the results would “guide the further course of action as well as bring clarity on the inputs received/to be received from WHO.”</p>
<p>The syrups had been approved for export only to the Gambia,
India says although the WHO says they may have gone elsewhere
through informal markets.</p>
]]></content:encoded>
      <category>World</category>
      <guid>https://english.aaj.tv/news/30300964</guid>
      <pubDate>Wed, 12 Oct 2022 14:50:18 +0500</pubDate>
      <author>none@none.com (Reuters)</author>
      <media:content url="https://i.aaj.tv/large/2022/10/12135957a769db0.webp?r=140344" type="image/webp" medium="image" height="480" width="800">
        <media:thumbnail url="https://i.aaj.tv/thumbnail/2022/10/12135957a769db0.webp?r=140344"/>
        <media:title>Logo of the Maiden Pharmaceuticals Ltd. company is seen on a board outside their office in New Delhi, India, October 6, 2022. Image via REUTERS/FILE
</media:title>
      </media:content>
    </item>
  </channel>
</rss>
